New tests of HepaLife Technologies Inc.’s bioartificial liver device demonstrated that the company’s bioreactor system and patented PICM-19 cells inside the device remain functional over prolonged periods time, far exceeding the number of treatment hours referenced in published research studies of human liver failure patients undergoing conventional liver support therapies. During the tests, HepaLife’s bioartificial liver device system was able to successfully retain the highest levels of liver-specific metabolic activity, mimicking the most important functions of the human liver, for 14 days. With these test results, the company has progressively moved towards the commercialization of the technology.